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Combating tuberculosis requires a detailed understanding of
how mycobacterial effectors modulate the host immune
response. The role of themultigenePE family of proteins unique
to mycobacteria in the pathogenesis of tuberculosis is still
poorly understood, although certain PE_PGRS genes have been
linked to virulence. Tumor necrosis factor- (TNF-) is essen-
tial for successfully combating tuberculosis. In this study we
provide evidence that PE_PGRS33, a surface exposed protein,
elicits TNF- release from macrophages in a TLR2 (Toll-like
receptor 2)-dependent manner. ASK1 (apoptosis signal-regu-
lating kinase 1) is activated downstream of TLR2. ASK1 acti-
vates the MAPKs p38 and JNK. PE_PGRS33-induced signaling
leads to enhanced expression of TNF- and TNF receptor I
(TNFRI) genes. Mycobacterium smegmatis expressing PE_
PGRS33 elicits the same effects as purified PE_PGRS33. TNF-
release occurs even when internalization of the bacteria is
blocked by cytochalasin D, suggesting that interaction of PE_
PGRS33 with TLR2 is sufficient to trigger the effects described.
Release of TNF- plays the determining role in triggering apo-
ptosis in macrophages challenged with PE_PGRS33. The death
receptor-dependent signals are amplified through classical
caspase 8-dependent mitochondrial release of cytochrome c,
leading to the activation of caspases 9 and 3. An important
aspect of our findings is that deletions within the PGRS domain
(simulating those occurring in clinical strains) attenuate the
TNF--inducing ability of PE_PGRS33. These results provide
the first evidence that variations in the polymorphic repeats of
the PGRS domain modulate the innate immune response.
Containing infection by microbial pathogens involves both
innate and adaptive arms of the host immune response. Tumor
necrosis factor- is a pleiotropic cytokine that plays an impor-
tant role in determining the outcome of tuberculosis by induc-
ing a range of cytokines and chemokines, as well as apoptosis
(1). It is widely accepted that TNF-5 is essential for the main-
tenance of the granuloma and the control of tuberculosis (2).
Hosts with a deficiency in TNF- or its receptors are suscepti-
ble to mycobacterial infection (3–8). TNF- controls both the
innate and the adaptive arms of the immune response against
tuberculosis. Recent studies have shown that TNF/ mice
undergo an uncontrolled expansion of CD4 andCD8T cells (9).
Patients receiving anti-TNF therapy for chronic inflammatory
diseases are susceptible to tuberculosis, providing evidence that
TNF- has a role in controlling tuberculosis in humans (10–
12). Considering its central role in defining the course of tuber-
culosis infection, it is important to understandhow themicrobe
regulates TNF- induction in the host and how this is related to
the regulation of key events such as the induction of proinflam-
matory cytokines/chemokines.
Because Mycobacterium tuberculosis resides in macro-
phages, the course of the infection rests on the outcome of the
interaction between the bacterium and the host macrophages.
Paradoxically, macrophages provide an intracellular niche for
the invading pathogen and also restrict the pathogen by a vari-
ety of mechanisms. This duality of function has been analyzed
in a recent report by Leemans et al. (13) who have suggested
that the bacterium resides in resting macrophages, whereas
activated macrophages deliver the antimicrobicidal arsenal
required to limit the pathogen. Apoptosis of resting macro-
phages is likely to be a part of the immune defense mechanism.
Mycobacteria-induced apoptosis of infected macrophages
releases mycobacterial antigen-containing apoptotic vesicles.
These vesicles are engulfed by dendritic cells, which process the
antigenic cargo for subsequent presentation toCD8Tcells (14).
Several lines of evidence suggest that TNF- plays a critical role
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in modulating apoptosis associated withM. tuberculosis infec-
tion. Inactivation of TNF- is linked to the ability ofM. tuber-
culosis to evade apoptosis of host macrophages (15, 16). Based
on the above, it is important to dissect the repertoire of myco-
bacterial molecules delivering TNF--dependent pro-apopto-
tic signals to macrophages, and to understand howmycobacte-
ria may have developed mechanisms to suppress these signals.
Eight percent of the coding sequence of the M. tuberculosis
genome is dedicated to members of the unrelated PE and PPE
gene families, characterized by the presence of N-terminal Pro-
Glu and Pro-Pro-Glu motifs in the respective families (17).
Linkage of glycine-rich sequences encoded by polymorphic
GC-rich repetitive sequences (PGRS) to the C-terminal ends of
the PE domains is characteristic of the PE_PGRS family of pro-
teins. Several PE_PGRS proteins are localized on the extracel-
lular surface of M. tuberculosis (18, 19). One such protein is
PE_PGRS33 (encoded by the open reading frameRv1818c ofM.
tuberculosisH37Rv) (20). A role of certain PE_PGRSproteins in
virulence was suggested by gene inactivation studies in Myco-
bacterium marinum. Inactivation of two PE_PGRS genes
resulted in a replication defect in macrophages and decreased
survival in granulomas (21). Global expression profiles have
shown that the PE/PPE genes are not regulated as one group,
but rather they show variable expression patterns under differ-
ent environmental conditions likely dictated by different regu-
latory circuits (22). The PE/PPE proteins are therefore likely to
fulfill diverse functions in the biology ofM. tuberculosis.
The host response to infection is initiated by the early
response of the innate immune system to an array of con-
served pathogen-associated molecular patterns. It is there-
fore likely that differences in the virulence ofM. tuberculosis
could relate to differences in this early response. The Toll-
like receptors (TLRs) are evolutionarily conserved pattern
recognition receptors (PRRs) that recognize pathogen-asso-
ciated molecular patterns (23). The diversity of the innate
immune response to pathogens is to a large extent generated
by the diversity of signaling triggered by the TLRs and their
adapters. Given that pathogenic mycobacteria infect profes-
sional phagocytes, there has understandably been consider-
able interest in deciphering how TLR-mediated signals can
control the innate immune response to mycobacteria. TLR2-
deficient mice have been reported to be susceptible to M.
tuberculosis infection (24), particularly in a high dose aerosol
challenge model (25).
The complementary approaches of using either individual
molecules or the intact bacterium modified in expression of a
particular molecule to study effects on host cell signaling in the
context of innate immunity contribute toward detailed under-
standing of immune signaling in response to mycobacterial
infection. In this study we have used both approaches to evalu-
ate how one member of the unique PE_PGRS family of M.
tuberculosis proteins, namely PE_PGRS33, regulates macro-
phage signaling. We provide evidence that the induction of
TNF- by PE_PGRS33 occurs in a TLR2-dependent manner
and leads to consequent macrophage apoptosis. The apoptotic
signals generated by PE_PGRS33-induced TNF- release are
amplified in a mitochondria-dependent pathway. The PGRS
domain is responsible for mediating TNF- release. The PGRS
domain of PE_PGRS33 shows a large number of variations in
clinical strains (26). The most important results of our study
reflect that the deletion of some of the PGRS repeats within
this domain (simulating the deletions that exist in putative
PE_PGRS33 proteins from clinical isolates of M. tuberculosis)
impact the TNF--inducing ability of the respective proteins.
These findings are of potential clinical relevance and suggest
that polymorphisms in the PGRS domain help clinical strains of
M. tuberculosis modulate the release of TNF- from macro-
phages. Thesemodulatory effects could potentially regulate the
clinical course of the disease.
EXPERIMENTAL PROCEDURES
Reagents—Antibodies against total and phospho-specific
MAPKs cleaved caspase 3, caspase 8, and caspase 9 were pur-
chased fromCell Signaling Technology, Beverly,MA. Antibod-
ies against ASK1, Bid, cyt c, -actin, and protein A/G (plus)-
agarose were purchased from Santa Cruz Biotechnology Inc.,
Santa Cruz, CA. SB203580, U0126, SP600125, Z-DEVD-FMK,
Z-LEHD-FMK, Z-IETD-FMK, and protease inhibitors were
from EMD Biosciences, San Diego 3,3-Dihexyloxacarbocya-
nine (DiOC6) and Alexa-488-conjugated anti-rabbit IgG were
obtained fromMolecular Probes Inc., Eugene, OR. Escherichia
coli lipopolysaccharide (LPS) and polymyxin B resin were from
Sigma. Annexin-fluos, Pefabloc, and protease inhibitormixture
were purchased from Roche Applied Science. Neutralizing
TLR-4 antibody (HTA 125) was purchased from Imgenex Bio-
tech, Bhubaneswar, India. Neutralizing anti-TLR2 antibody
was a generous gift from Carsten Kirschning, Institute of Med-
ical Microbiology, Immunology, and Hygiene, Technical Uni-
versity of Munich.
Plasmid Constructs—Wild type and dominant-negative
murine TLR2, as well as murine TLR4, have been described
earlier (27). cDNA of human TLR2 was obtained by RT-PCR
from a total RNA preparation fromTHP-1 cells using the sense
and antisense primers pairs 5-ATAAAGCTTATGCCACAT-
ACTTTGTGG-3 and 5-ATGGATCCCTAGGACTTTATC-
GCAGCT-3, respectively. The resulting PCR product was
cloned between the HindIII and BamHI sites (underlined) of
pFLAG-CMV-6a.HumanTLR4was similarly reverse-transcribed
using the sense and antisense primers 5-ATGGATCCGCATG-
GAGCTGAATTTCTA-3 and 5-ATAAAGCTTCTAAGATG-
TTGCTTCCTG-3, respectively and cloned between the BamHI
and HindIII sites (underscored) of pcDNA3.1. Hemagglutinin-
tagged wild type ASK1 (ASK1, WT) and a catalytically inactive
mutant (K709M) of ASK1 (ASK1, KM) were obtained from
Hidenori Ichijo, Graduate School of Pharmaceutical Sciences,
TheUniversity of Tokyo, Japan. FLAG-tagged p38 and its dom-
inant-negative mutant (p38 (agf)), as well as FLAG-tagged JNK
and its dominant-negative mutant (JNK(apf)) were obtained
fromRogerDavis, University ofMassachusettsMedical School,
Worcester, MA. Cells were routinely transfected using
FuGENE 6 (Roche Applied Science) according to the manufac-
turer’s instructions.-Galactosidase reporter plasmidwas used
to normalize transfection efficiencies.
Culture of the Murine Macrophage Cell Line RAW 264.7 and
Human Embryonic Kidney Cell Line HEK293—The murine
macrophage cell line RAW 264.7 and the human embryonic
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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kidney cell line HEK293 were obtained from the National Cen-
ter for Cell Science, Pune, India. RAW 264.7 was maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 units/ml peni-
cillin, and 100g/ml streptomycin in a humidified atmosphere
containing 5% CO2. Dishes were washed to remove nonadher-
ent cells. Adherent cells were 95% viable as determined by
trypanblue dye exclusion.HEK293 cellswere grownunder sim-
ilar conditions in modified Eagle’s medium supplemented with
10% heat-inactivated FBS, 100 units/ml penicillin, and 100
g/ml streptomycin.
Cloning and Expression of PE_PGRS Genes—The PE_
PGRS33 gene (Rv1818c) was amplified by PCR using
genomic DNA ofM. tuberculosis H37Rv (kind gift from Jaya
Tyagi, All India Institute of Medical Sciences, New Delhi) as
template and the primers 5-ATGGATCCATGTCATTTG-
TGGTCACGA-3 (sense) (primer A) and 5-ATGAATCC-
CTACGGTAACCCGTTCATC-3 (antisense) (primer B)
with BamHI and EcoRI sites (underscored), respectively, and
cloned between asymmetric BamHI and EcoRI sites in the
vector pET28a (Novagen) for expression. The resulting
plasmid is designated pJSK33. The gene encoding the PE
domain (amino acid residues 1–140) of the same protein was
amplified by PCR using the sense primer given above and the
antisense primer 5-ATGAATTCCTAGCCGATCAAGAT-
TCCC-3, and cloned between the BamHI and EcoRI sites of
pET 28a to generate pJSK34. The genes encoding PE_
PGRS62 (Rv3812) and PE_PGRS48 (Rv2853) were amplified
by PCR using the primer pairs 5-TAGGATCCATGTCGTTC-
GTGGTCACAGT-3 (sense) and 5-AATGAATTCTAAGC-
CGCCGGTTTGATT-3 (antisense) for PE_PGRS62 and 5-
TAGGATCCATGTTGTATGTAGTTGCG-3 (sense) and 5-
TTAGAATTCAGCCGGGCTGCCCGGGGT-3 (antisense)
for PE_PGRS48. The resulting PCR products were cloned
between the BamHI and EcoRI sites of pET28a to generate
pJSK35 and pJSK36 for PE_PGRS62 and PE_PGRS48, respec-
tively. For point mutations and deletion constructs (Gly-217
toGly-219),(Gly-227 toGly-229),(Gly-186 to Ala-188), and
(Ala-198 to Gly-203), of PE_PGRS33, site-directed mutagen-
esiswas carried out by overlap extensionPCRusing appropriate
primers and pJSK33 as template. Other deletion constructs
were obtained by two-step PCR and subsequent cloning
between the BamHI and EcoRI sites of pET28a. The first PCR
product was obtained using the sense primer 5-ATGGATC-
CATGTCATTTGTGGTCACGA-3 and the antisense primers
shown in Table 1. The second PCR product was obtained using
the antisense primer 5-ATGAATTCCTACGGTAACCCGT-
TCATC-3 and the sense primers shown inTable 1. SA-440 and
SA455 variants of PE_PGRS33 (described under Fig. 1) were
PCR-amplified using primers described by Talarico et al. (26)
and genomic DNA of the respective clinical isolates (26) and
cloned in pUC19. A second round of PCR was performed using
the respective pUC19 constructs and primer pairs A and B,
followed by cloning in pET28a as described above. All con-
structs were verified by sequencing of both strands.
Induction of PE_PGRS33 from E. coli BL21 (DE3)/pJSK33
was carried out at 37 °C for 4 h with isopropyl thio--D-galac-
toside (250 M). Cells were harvested, and the cell pellet was
resuspended and lysed with Bugbuster HT (Novagen) to which
0.5 mM EDTA and 100 M Pefabloc was added. Hexa-His-
tagged PE-PGRS33 was purified from the soluble fraction by
chromatography on Ni2-NTA-agarose (Qiagen). All experi-
ments were carried out with the purified PE-PGRS33 produced
in E. coli unless otherwise stated. For expression of variant
PE_PGRS proteins, E. coli strains Rosetta (Novagen) and
C41(DE3) (Avedis, France) were also used. Variant PE_PGRS
proteins were purified by chromatography onNi2-NTA affin-
ity chromatography.
Cloning and Expression of PE_PGRS33 in HEK293—To
generate a Myc-His epitope tag in pcDNA3.1 ()(Invitro-
gen), the Myc-His epitope present in pBAD-Myc-HisB
(Invitrogen) was amplified using the sense and antisense
primers 5-CGGGATCCGAACAAAAACTCATCT-3 and
5-CCCAAGCTTAAGCTGGAGACCGTT-3, respectively.
The resulting PCR product was cloned between the BamHI
and HindIII sites (underlined) of pcDNA3.1() to generate
the vector pcDNA3.1-Myc-His. PE_PGRS33 was amplified
by PCR using the primer pairs 5-TGCTCTAGAATGTCA-
TTTGTGGTCACGA-3 (sense) and 5-CGGAATTCATC-
GGTAACCCGTTCATCC-3 (antisense). The resulting
PCR product was cloned between the XbaI and EcoR1 sites
(in boldface) of pcDNA3.1-Myc-His to generate pJSK37.
107 HEK293 cells were transfected with pJSK37 using the
Polyfect transfection reagent (Qiagen). Cells were rinsed
(twice) with ice-cold PBS, scraped off, and homogenized with a
26-gauge needle in 1 ml of buffer (25 mM Tris-HCl, pH 7.6, 1
mM EGTA, aprotinin (5 g/ml), leupeptin (10 g/ml), and 1
mM Pefabloc). His-tagged PE_PGRS33 was purified from the
cytosolic fraction by chromatography on Ni2-NTA-agarose.
LPS Assay—LPS contamination of the purified protein was
determined by Limulus amoebocyte lysate assay using the
E-TOXATE kit from Sigma with a sensitivity limit of 0.1
endotoxin unit/ml.
Ectopic Expression of His6-PE-PGRS33 in M. smegmatis—
Briefly, theHis-PE-PGRS33 gene was cloned in a shuttle vector
carrying the mycobacterial and E. coli origins of replication
under the control of the hsp60 promoter (28) to generate
pJSK101. For ectopic expression of His-PE_PGRS33, pJSK101
was electroporated into M. smegmatis mc2155. Expression of
His-PE-PGRS33 was confirmed by Western blotting of the
lysates from exponentially growing M. smegmatis/pJSK101
with anti-His antibody.
TABLE 1
Primers used for the generation of deletion constructs of PE_PGRS33
Antisense primer for 1st fragment Sense primer for 2nd fragment Mutation
5-ATGGTACCGCCGAACCCTGCGGTG-3 5-ATGGTACCGGGGCCGGCGGGGCCG-3 (Gly-184 to Gly-213)
5-ATGGTACCGGCGCCGTAGAGCAGCCC-3 5-ATGGTACCGGCGGGGCCGGCGGAG-3 (Gly-196 to Asp-243)
5-ATGGTACCGAGTCCGCCGACGCCG-3 5-ATGGTACCATCGGATTGGTCGGGAAC-3 (Leu-237 to Gly-327)
5-ATGGTACCGGCGTTGCCGCCCGCCC-3 5-ATGGTACCGGCCTTCTGTTTGGTACC-3 (Gly-372 to Ala-403)
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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Challenge of RAW 264.7 with Bacteria—RAW 264.7 cells
were infected with M. smegmatis harboring vector alone or
pJSK101 expressing PE_PGRS33 atmultiplicities of infection of
5, 10, and 20 for various periods of time. Cytochalasin D was
used to prevent internalization of bacteria (29). Cells were
treated with cytochalasin D (5 M) for 1 h followed by washing
three times with PBS before infection with M. smegmatis. To
determine the survival of bacteria within macrophages, infected
macrophages were washed with PBS and lysed with 0.05% SDS.
The lysates were serially diluted and plated on Middle Brook
7H11 agar, and colony-forming units were determined.
Isolation of Monocyte-derived Macrophages (MDM)—MDM
were isolated as described by Manor and Sarov (30). Briefly,
human peripheral blood monocytes were prepared from hepa-
rinized blood of normal healthy volunteers (with informed con-
sent), by density gradient centrifugation on Ficoll-Paque
(Sigma). Cells from the interface were washed three times, sus-
pended in RPMI 1640 containing HEPES buffer, and incubated
in plastic dishes for 2–3 h at 37 °C in aCO2 incubator. Adherent
monocytes were removed from the plate by gentle scraping.
Monocytes obtained were incubated for 7–10 days in RPMI
with 10% FBS in a CO2 incubator when 95% of monocytes were
converted to MDM.
Cell Death—For the detection of histones by ELISA, cells
were plated (6  104cells/well) on 96-well plates. After treat-
ments, cell death was detected with the cell death detection
ELISA Plus kit (Roche Applied Science) according to the man-
ufacturer’s protocol. For measurements of annexin-fluos bind-
ing, 100 l of cells in annexin-fluos binding buffer (10 mM
HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2) were mixed
with 2 l of annexin-fluos. The mixture was incubated for 15
min at room temperature, washedwith binding buffer, and ana-
lyzed by flow cytometry. To assess necrosis, propidium iodide
(1 g/ml) was added to the cell suspension just before analysis.
Unless otherwise stated, cell death was analyzed 20 h after chal-
lenge with PE_PGRS33 (or PE_PGRS62 or PE_PGRS48).
Study of the Interaction of PE_PGRS33 with TLR2—Lysates
from RAW 264.7 cells (107 cells/assay) were incubated with
Ni2-NTA or PE_PGRS33-bound Ni2-NTA-agarose at 4 °C
for 2 h with shaking. The beads were washed and boiled in 2
Laemmli buffer for 5 min, and proteins were separated by 7.5%
SDS-PAGE, transferred onto a polyvinylidene difluoride mem-
brane, and immunoblotted with anti-TLR2 antibody to detect
His-PE_PGRS33-bound TLR2. In separate experiments,
HEK293 cells transfected either with TLR2 or with TLR4 were
incubated for 10minwithHis-PE_PGRS33. Plates werewashed
with PBS and scraped out in PBS containing 1% bovine serum
albumin (BSA). Pelleted cells were incubated with rabbit anti-
His antibody (Cell Signaling Technology, Beverly, MA) for 1 h
at 4 °C. Pellets were washed twice with PBS and 1% BSA and
incubated with 2 g/ml Alexa 488-conjugated anti-rabbit IgG
in 250 l of PBS and 1% BSA for 45 min on ice. Pellets were
washed twice, resuspended in 1 ml of PBS, and subjected to
fluorescence-activated cell sorter analysis. 10,000 cells were
counted for each condition.
Treatment of RAW 264.7 Cells with PE_PGRS33 and Prepa-
ration of Cell Lysates—RAW 264.7 cells were cultured in
24-well tissue culture plates at 4  105 cells/well, treated with
PE_PGRS33, and lysed with lysis buffer (20 mM Tris-HCl, pH
7.4, containing 1% (v/v) Nonidet P-40, 10% (v/v) glycerol, 137
mM NaCl, 20 mM NaF, 1 mM EDTA, 40 mM sodium -glycero-
phosphate, 4g/ml each of leupeptin, pepstatin, and aprotinin,
1 mM Na3VO4, 1 mM Pefabloc, and 1 mM benzamidine) on ice
for 15 min. Cell lysates were boiled for 5 min after the addition
of 5 Laemmli sample buffer and subjected to Western blot-
ting. When performing Western blotting for detection of
caspases, cells were pelleted and freeze-thawed three times in
20 l of cell extraction buffer (50 mM PIPES/NaOH, pH 6.5,
containing 2 mM EDTA, 0.1% (w/v) CHAPS, 5 mM dithiothrei-
tol, 20 g/ml leupeptin, 10 g/ml pepstatin, 10 g/ml aproti-
nin, and 1 mM Pefabloc). The lysates were centrifuged at
10,000  g for 5 min at 4 °C, and the supernatants were col-
lected for the detection of caspases.
Western Blotting—Proteins were separated on SDS-polyac-
rylamide gels and then transferred electrophoretically to poly-
vinylidene difluoride membranes. The blots were blocked with
5% nonfat dry milk and subsequently incubated overnight at
4 °C with primary antibodies in Tris-buffered saline containing
1% (v/v) Tween 20 (TBST) and 5% (w/v) BSA. After washing,
the blots were incubated with horseradish peroxidase-conju-
gated goat anti-rabbit IgG (Cell Signaling Technology) (or
appropriate secondary antibody) in blocking buffer for 1 h at
room temperature, followed by development with BM chemi-
luminescence reagent (Roche Applied Science), and exposed to
x-ray film (Kodak XAR5; Eastman Kodak Co.).
ASK1 Kinase Assay—This was done as described by Bhatta-
charyya et al. (31). RAW 264.7 cells were cultured in 24-well
tissue culture plates at 6 105 cells/well. After treatment, cells
were lysed with lysis buffer containing 20mMTris-HCl, pH 7.5,
150mMNaCl, 1mMEDTA, 1mMEGTA, 1% (v/v) TritonX-100,
1% sodium deoxycholate, 0.5 mM sodium pyrophosphate, 1mM
sodium -glycerophosphate, 1 mM Na3VO4, and 1 g/ml leu-
peptin. The supernatant (equivalent to 200 g of protein) was
incubated overnight at 4 °C with rabbit polyclonal ASK1 anti-
body. Protein A/G Plus-agarose was added and incubated at
4 °C for an additional 3 h. The beads were washed twice with
lysis buffer and twice with kinase buffer (25 mM Tris-HCl, pH
7.5, containing 5 mM sodium -glycerophosphate, 2 mM dithi-
othreitol, 0.1 mM Na3VO4, and 10 mM MgCl2). The pellet was
washed once with kinase buffer without protease inhibitors.
The beads were then incubated in 20 l of kinase buffer in the
presence of 0.5 Ci of [-32P]ATP (specific activity, 6000
Ci/mmol)with 1g ofmyelin basic protein as substrate at 30 °C
for 15 min. The reaction was stopped by adding protein gel
denaturing buffer. After SDS-PAGE, gels were dried and sub-
jected to autoradiography.
Isolation of Cytosol and Mitochondrial Fractions for Detec-
tion of Cyt c and Bid—After the treatments, 18 106 cells were
suspended in 400 l of suspension buffer (20 mM HEPES, pH
7.5, containing 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1mMPefabloc, 10g/ml leupeptin, 10g/ml aprotinin,
and 150 mM sucrose) and broken by 20 passages through a
26-gauge needle. The homogenate was centrifuged at 750  g
for 10min to remove nuclei and unbroken cells. Themitochon-
drial pellet was obtained by centrifugation at 10,000 g for 15
min and resuspended in 40 l of resuspension buffer (20 mM
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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Tris-HCl, pH 7.4, containing 100 mM NaCl, 1 mM Pefabloc, 10
g/ml leupeptin, and 10 g/ml aprotinin). The supernatant
obtained by centrifugation at 100,000 g for 60min at 4 °Cwas
the cytosolic fraction. BeforeWestern blotting, protein concen-
trations were assayed, and all samples were normalized to equal
protein concentrations. Blots probed with anti-cyt c antibody
were stripped and reprobed for -actin expression to confirm
equal loading in all lanes.
Measurement of Mitochondrial Membrane Potential—The
induction of the mitochondrial permeability transition was
determined in intact cells as the reduction in the accumulation
of DiOC6 (32). Briefly, 5  105 RAW 264.7 cells were loaded
with DiOC6 (100 nM) during the last 30 min of treatment with
PE_PGRS33 and then lysed in deionized water, and fluores-
cence of DiOC6was read in aHitachi F-4500 fluorescence spec-
trophotometer at excitation and emission wavelengths of 488
and 500 nm, respectively. Values for de-energized mitochon-
dria were determined by simultaneous treatment of cells with
10 M carbonyl cyanide m-chlorophenylhydrazone (CCCP)
and DiOC6.
Measurement of TNF- in Culture Supernatants—Cells
after treatment with inhibitors or after transfections were
incubated with PE_PGRS33 (or its mutants) or PE_PGRS62
or PE_PGRS48. The conditioned medium was removed and
assayed for TNF- by ELISA using the murine Biotrak
TNF- assay kit (Amersham Biosciences) according to the
manufacturer’s protocol.
RNA Isolation and RT-PCR—Total RNA was prepared from
cells using the RNeasy mini kit (Qiagen) according to the man-
ufacturer’s protocol. 100 ng of RNA was reverse-transcribed
using the Titanium One-step RT-PCR kit (Clontech). The
sense and antisense primers 5-GGCAGGTCTACTTTGGA-
GTCATTGC-3 and 5-ACATTCGAGGCTCCAGTGAAT-
TCGG-3, respectively, were used to amplify 299 bp of the
murine TNF- mRNA. The sense and antisense primers 5-
CGGACATGGGTCTCCCCACCG-3 and 5-AACCCTGC-
ATGGCAG-3, respectively, were used to amplify 529 bp of
the murine TNFRI mRNA. The PCR conditions for TNF-
mRNA amplification were denaturation at 94 °C for 30 s,
annealing at 60 °C for 30 s, and extension at 68 °C for 1 min for
35 cycles. For TNFRI, annealing was carried out at 52 °C. Glyc-
eraldehyde-3-phosphate dehydrogenase (gapdh) was amplified
using the primers 5-CCA TCA ATG ACC CCT TCA TTG
ACC-3 (sense) and 5-GAA GGC CAT GCC AGT GAG CTT
CC-3 (antisense) to generate a 604-bp product.
Analysis of Surface Expression of TNFRI by Flow Cytometry—
Surface-exposed TNFRI was quantitated by flow cytometry.
Cells before or after treatment were incubated with TNFRI
antibody or isotype control IgG for 30 min, washed with PBS,
and incubated with Alexa-488-conjugated anti-rabbit IgG for
30 min. The cells were then washed three times with PBS and
analyzed by flow cytometry. 10,000 cells were counted for each
condition.
Statistical Analysis—Data are represented as the means 
S.D. of separate experiments. Analysis of variance and Student’s
t test were performed to test statistical significance. A p value of
0.05 was considered statistically significant.
RESULTS
PE_PGRS33 Stimulates Release of TNF- from RAW 264.7
Macrophages—The ability of His-PE_PGRS33 to stimulate
TNF- release was studied in the macrophage cell line RAW
264.7. Recombinant His-PE_PGRS33 stimulated the release of
TNF- from RAW 264.7 macrophages in a time-dependent
(Fig. 1A) and dose-dependent manner (Fig. 1B).
PE_PGRS33-inducedTNF-Release IsNeither Because ofHis
Tag nor LPS—To control for nonspecific effects of the His tag
present in recombinant PE_PGRS33, the TNF--inducing abil-
ity of two different His-tagged PE_PGRS proteins was tested in
parallel. Neither His-tagged PE_PGRS48 nor PE_PGRS62
could induce TNF- release above the level observed in control
cells (Fig. 1C), ruling out the likelihood of the His tag contrib-
uting toward the TNF--inducing ability. These results also
suggest that the TNF--inducing ability is specific for PE_
PGRS33 and is not a common feature of the PE_PGRS family.
Heat treatment inhibited the TNF--inducing ability of PE_
PGRS33 (Fig. 1C), whereas polymyxin B treatment was without
effect (Fig. 1C), ruling out the possibility that the observed
induction of TNF- was because of the contamination of LPS.
The PE domain of PE_PGRS33 alone was not able to elicit the
release of TNF- (Fig. 1D). This further suggests that the
observed effects are dependent on the PGRS domain of PE_
PGRS33 rather than being attributable to any contaminating
factors. His-PE_PGRS33 was also expressed and purified from
HEK293 cells. This protein could also elicit TNF- release from
RAW 264.7 macrophages (Fig. 1C). This confirmed that the
observed effect of PE_PGRS33 was not because of contaminat-
ing bacterial products.
Mutations of PE_PGRS33 Affect TNF- Release—Taking the
gene sequence of PE_PGRS33 ofM. tuberculosisH37Rv as ref-
erence, Talarico et al. (26) have recently shown a large number
of sequence variations in the PE_PGRS33 gene in clinical iso-
lates of M. tuberculosis. These variations include synonymous
and nonsynonymous single nucleotide polymorphisms,
in-frame insertions and deletions, and deletion resulting in
frameshift, which were mainly found in the PGRS-encoding
domain. To relate these genetic variations with the TNF--
inducing ability of PE_PGRS33, we mimicked some of these
mutations by genetic manipulation of PE_PGRS33, expressed
the corresponding recombinant proteins with a His tag, and
studied the release of TNF- by these variants. Pointmutations
S178A, V234A, G320A, G389A, T391I, and deletions of amino
acids Gly-217 to Gly-219, Gly-227 to Gly-229, and Ala-198 to
Gly-203, all variations in the PGRS domain, did not have signif-
icant effect on TNF--inducing ability of exogenous PE_
PGRS33. However, the deletions from Gly-184 to Gly-213,
from Gly-196 to Asp-243, from Leu-237 to Gly-327, and from
Gly-372 to Ala-403 all attenuated PE_PGRS33-induced release
of TNF- from RAW 264.7 cells (Fig. 1D).
PE_PGRS33 Signals through TLR2—To test whether PE_
PGRS33 signals by interacting with cell surface receptors, we
focused on the TLR family. Transfection of RAW 264.7 with
dominant-negative TLR2, but not with dominant-negative
TLR4, inhibited the TNF--inducing ability of PE_PGRS33
(Fig. 2A) suggesting that PE_PGRS33 likely signals through
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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TLR2. The HEK293 cell line does not express TLR2 or TLR4.
To confirm our view that PE_PGRS33 signals specifically
through TLR2, we transfected HEK293 cells either with TLR2
or with TLR4. PE_PGRS33 could elicit TNF- release from
HEK293 cells transfectedwithTLR2 but not fromHEK293 cells
transfected with TLR4 (Fig. 2B). PE_PGRS33 could also elicit
TNF- release from MDM (Fig. 2C). This could be blocked by
neutralizing antibody against TLR2 (Fig. 2C) but not with neu-
tralizing antibody against TLR4 (Fig. 2C) or isotype-specific
antibody (data not shown) further supporting a crucial role of
TLR2 in PE_PGRS33-mediated TNF- release.
Interaction of PE_PGRS33 with TLR2—To test whether
PE_PGRS33 interacts with TLR2, RAW 264.7 cell lysates were
incubated with PE_PGRS33 immobilized on Ni2-NTA-agar-
ose. Western blots probed with anti-TLR2 antibody showed
that TLR2 was pulled down with immobilized PE_PGRS33 in
the absence or in the presence of polymyxin B (Fig. 2D), sug-
gesting an interaction between PE_PGRS33 and TLR2 inde-
pendent of any possible contamination by LPS. TLR2 could not
be pulled down either in a control tube containing Ni2-NTA-
agarose alone or when an irrelevant His-tagged protein was
immobilized on Ni2-NTA agarose, confirming a specific
interaction between PE_PGRS33 and TLR2. No band appeared
in Western blots performed using anti-CD14 or anti-TLR4
antibody as negative controls (data not shown), confirming that
the band that was visible after pulldown could be attributed
specifically to TLR2. To confirm that TLR2 was the receptor of
PE_PGRS33, we also analyzed the binding of PE_PGRS33 to
TLR2-transfectedHEK293 cells by flow cytometry. There was a
dose-dependent increase in PE_PGRS33 binding to TLR2-
transfected HEK293 cells (Table 2). We also tested binding of
PE_PGRS33 to HEK293 cells transfected with TLR4. In this
case, binding of Alexa-488 did not show any increase in con-
centrations of PE_PGRS33 (up to a concentration of 5 g/ml)
(data not shown). These results argued in favor of a specific
interaction between PE_PGRS33 and TLR2.
TNF- Release fromMacrophages Challenged with M. smeg-
matis Harboring PE_PGRS33—To analyze the effects of PE_
PGRS33 on RAW 264.7 macrophages in the context of the
bacterium as a whole, we compared the relative ability of trans-
formants of M. smegmatis ectopically expressing PE_PGRS33
or harboring the empty vector alone to release TNF-. PE_
PGRS33 expressed inM. smegmatis has been demonstrated to
were treated with recombinant PE_PGRS33 or PE_PGRS62, or PE_PGRS48
(produced in E. coli) as indicated. Cells were also treated with recombinant
PE_PGRS33 produced in HEK293 (PE_PGRS33 (HEK)) at a concentration of 1
g/ml. D, cells were treated with recombinant full-length PE_PGRS33 (wt) or
the PE domain (amino acid residues 1–140) or different mutants of PE_
PGRS33 as indicated. SA440 represents PE_PGRS33 expressed from a gene
carrying a 107-bp deletion from 710 to 816 bp (36 amino acids), as well a
32-bp insertion at 817 bp (after amino acid 272, leading to the insertion of 11
amino acids). SA455 represents PE_PGRS33 expressed from a gene carrying a
single nucleotide polymorphism (T 3 C transition at position 717), a 9-bp
insertion at 1240 bp (resulting in the insertion of a Gly-Ala-Gly sequence after
amino acid 413) and an 18-bp insertion at 597 bp (resulting in the insertion of
Gly-Ala-Gly-Gly-Ala-Gly after amino acid 199). The numbering is based on the
nucleotide andamino acid sequences of PE_PGRS33ofM. tuberculosisH37Rv.
In all cases incubationwas carried out for 14 h, and released TNF-wasmeas-
ured in the supernatant. All values aremeans S.D. for three separate sets of
experiments. *, p 0.01; versus control treatedwith full-length PE_PGRS33 of
M. tuberculosis H37Rv (WT).
FIGURE 1. Release of TNF- induced by PE_PGRS33. RAW 264.7 cells were
incubated with PE_PGRS33 (1 g/ml) for different periods of time (A) or with
different concentrations of PE_PGRS33 for 14 h (B). C, PE_PGRS33 was sub-
jected to boiling for 1 h (heat) or was treated with polymyxin B (PB) resin. For
the latter, 100 l of PE_PGRS33 was mixed with 100 l of polymyxin B resin
and incubated at 4 °C for 1 h. Beads were removed, and the supernatant was
used to induce TNF-. In all experiments recombinant PE_PGRS33 purified
from E. coli was used unless otherwise stated. In separate experiments, cells
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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be surface-expressed (20). RAW 264.7 cells were challenged
with M. smegmatis containing the vector alone or the vector
harboring the PE_PGRS33 gene at a multiplicity of infection of
10 for various periods of time. Macrophages infected with M.
smegmatis release TNF- (8). This likely depends both on sig-
nals originating at the cell surface and on signals generated by
intracellular PRRs. Based on our observations that PE_PGRS33
interacts with TLR2, we confined our interest to analyzing spe-
cifically the effect of interaction of PE_PGRS33 with surface-
exposed receptors. Internalization of the bacteria was inhibited
by preexposure to cytochalasin D, an actin depolymerization
drug (to inhibit phagocytosis). Inhibition of phagocytosis was
confirmed by determining colony-forming units before and
after challenge of cytochalasin D-treated RAW 264.7 cells with
M. smegmatis. For TNF- measurement, M. smegmatis was
added to cytochalasin D-treated RAW 264.7. 18 h after chal-
lenge, M. smegmatis harboring empty vector released 1  0.2
ng/ml (n 4) TNF- from RAW 264.7 macrophages, whereas
M. smegmatis harboring the PE_PGRS33 gene released 4 0.5
ng/ml TNF- from RAW 264.7 (n  4). TNF- release
decreased to the level of 1  0.3 ng/ml (n  4) when cytocha-
lasinD-treated cellswere also pretreatedwith neutralizing anti-
TLR2 antibody, suggesting that the initial interaction of
PE_PGRS33 with surface-exposed TLR2 was sufficient for
TNF- release. The above results suggest that PE_PGRS33
expressed in the bacterium gives the bacterium the ability to
elicit TNF- in a TLR2-dependent manner.
PE_PGRS33 Stimulates TNF- Gene Expression—To deter-
mine whether the effect of PE_PGRS33 on TNF- release was
attributable to regulation at the level of TNF- gene transcrip-
tion, we analyzed the expression ofTNF- in PE_PGRS33-chal-
lenged macrophages by RT-PCR. Compared with untreated
cells, PE_PGRS33 elicited the time-dependent expression of
TNF- (Fig. 3). This was abrogated in cells pretreatedwith neu-
tralizing antibody against TLR2 (Fig. 3), suggesting that the
FIGURE 3. RT-PCR analysis of PE_PGRS33-induced expression of TNFRI
and TNF-. RAW 264.7 cells were left untreated or treated with PE_PGRS33
for different periods of time. In a separate experiment, cells were pretreated
with neutralizing TLR2 antibody (anti-TLR2) or isotype IgG (i/c) for 1 h, fol-
lowed by incubationwith PE_PGRS33 for 8 h. RNAwas isolated from the cells,
and RT-PCR was carried out according to the manufacturer’s protocol. DNA
was separated on agarose gel and visualized by staining with ethidium bro-
mide. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified
as control for all experiments.
TABLE 2
Binding of PE_PGRS33 to TLR2-transfected HEK293
His-PE_PGRS33 % Alexa-488-positive cellsa
g/ml
0 8 1
0.5 32 4b
1.0 58 5b
2.0 60 6b
a The results represent the means S.D. of three separate determinations.
b p 0.001 versus cells not exposed to His-PE_PGRS33.
FIGURE 2. PE_PGRS33 signals through TLR2. RAW 264.7 (A) or HEK293 (B)
cells were transfectedwithwild type (wt) or dominant-negative (dn) TLR con-
structs as indicated. Transfected cellswere either left untreated () or treated
(f) with PE_PGRS33 (1g/ml) for 14 h.C,humanperipheral bloodMDMwere
pretreated with neutralizing anti-TLR2 or -TLR4 antibody for 1 h. Cells were
then incubated without or with PE_PGRS33 (1 g/ml) in fresh medium for
14 h. In all cases, the release of TNF- was measured in the supernatant.
Values are the means S.D. of three different experiments. D, lysate from
RAW 264.7 cells was incubated with PE_PGRS33 immobilized with Ni2-
NTA-agarose in the absence or presence of polymyxin B or with Ni2-NTA-
agarose alone or with an irrelevant His-tagged protein immobilized on
Ni2-NTA-agarose for 2 h; the agarose-bound proteins were separated by
SDS-PAGE and immunoblottedwith anti-TLR2 antibody. The 1st lane is the
positive control representing immunoprecipitated TLR2 only.
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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TLR2-dependent regulation ofTNF- release by PE_PGRS33 is
likely at the transcriptional level.
PE_PGRS33-induced TNF- Release Is Dependent on the
MAPKs p38 and JNK—To elucidate the PE_PGRS33-induced
signaling downstream of TLR2, we focused on the MAPKs.
PE_PGRS33 elicited a time-dependent activation of p38 (Fig.
4A) and JNK (Fig. 4B) MAPKs. It was observed that inhibition
of ERK1/2 signaling byU0126 did not affect TNF- release (Fig.
4C). On the other hand, treatment of cells with the p38 MAPK
inhibitor SB203580 or the JNK inhibitor SP600125 led to
decrease in TNF- release (Fig. 4C) A combination of both
inhibitors could inhibit the release of TNF- to the extent of
	90%. Taken together, these results suggest that PE_PGRS33-
mediated TNF- release is dependent on signalingmediated by
the MAPKs p38 and JNK.
PE_PGRS33-induced TNF- Release Depends on the TLR2-
dependent Activation of the Mitogen-activated Protein Kinase
Kinase Kinase (MAPKKK) ASK1—The activation of the stress-
activated protein kinases p38 and JNK is the culmination of a
cascade of phosphorylation events mediated by MAPKK and
MAPKKK. The MAPKKK ASK1 is a key mediator in p38 and
JNK activation (33–35). The role of ASK1 in mycobacteria-
mediated signaling in macrophages has been demonstrated by
us in previous studies (31). ASK1 has also been shown to induce
p38 MAPK activation downstream of TLR2 signaling initiated
by mycoplasmal lipoprotein and staphylococcal peptidoglycan
(36). In the present instance, PE_PGRS33 was found to activate
ASK1 in a time-dependent manner (Fig. 4D). Transfection of
RAW 264.7 cells with dominant-negative TLR2 abrogated the
activation of ASK1, suggesting that PE_PGRS33-mediated
ASK1 activation is dependent on TLR2 (Fig. 4E). At the same
time, ASK1(KM) could inhibit the activation of p38 (Fig. 4F)
and JNK (Fig. 4G) MAPKs as well as the release of TNF- (Fig.
4H). Taken together, these results support the view that the
TLR2/ASK1/p38, JNK signaling axis is central to the PE_
PGRS33-induced release of TNF-.
PE_PGRS33-mediated Cell Death Is Dependent on TNF-—
Considering that activation of ASK1 and TNF- have in many
instances been related to the triggering of apoptotic signaling,
we investigated whether PE_PGRS33 could induce cell death in
RAW 264.7 cells. PE_PGRS33 could induce apoptosis in RAW
264.7 cells in a time- (Fig. 5A) and dose-dependentmanner (Fig.
5B) as assessed by histone ELISA. Cell death was also assessed
bymeasuring the binding of annexin-fluos to treated cells. This
method also supports the view that PE_PGRS33 is an apo-
ptosis-inducing protein (Table 3). Using propidium iodide
staining, no necrosis was observed in the treated cells. Other
PE_PGRS proteins such as PE_PGRS62 and PE_PGRS48
were unable to induce cell death in RAW 264.7 macro-
phages, suggesting that the death-inducing property is not
common to all members of this family.
We next evaluated whether PE_PGRS33 expressed by M.
smegmatis could elicit macrophage cell death. To exclude
effects exerted by M. smegmatis only after internalization,
RAW 264.7 cells were pretreated with cytochalasin D as
described above. Cells were then challengedwithM. smegmatis
harboring vector alone. 24 h after challenge, no significant
increase in histone release over that in cells that had not been
challenged with the bacteria was observed. M. smegmatis har-
boring the PE_PGRS33 gene could, on the other hand, elicit a
4  0.5-fold (n  4, p  0.05) greater release of histone in
cytochalasin D-treated RAW 264.7 compared with cells that
had not been challengedwith the bacteria. Pretreatment of cells
with anti-TLR2-neutralizing antibody abrogated the ability of
M. smegmatis/PE_PGRS33 to elicit cell death in cytochalasin
D-treated RAW 264.7 cells (data not shown).
TLR2 can recruit Fas-associated death domain to stimulate
apoptosis in a variety of situations (37). Because PE_PGRS33
FIGURE 4. PE_PGRS33-induced TNF- release depends on ASK1 and
MAPKs. A and B, RAW 264.7 cells were left untreated or treated with PE_
PGRS33 (1g/ml) for different periods of time. Cell lysateswereprepared and
separated on SDS-PAGE followed by immunoblotting with antibody against
phospho-p38 or phospho-JNK MAPK. C, RAW 264.7 cells were treated with
vehicle alone or MAPK inhibitors individually or in combination for 60 min
followed by removal of inhibitors and incubation without () or with (f)
PE_PGRS33 (1 g/ml) for 14 h. The release of TNF- was measured in the
supernatant. *, p  0.001; **, p  0.05, versus control (vehicle) treated with
PE_PGRS33.D and E, RAW264.7 cells were treatedwith PE_PGRS33 for differ-
ent periods of time (D), or cells were transfected with empty vector or
dominant-negative (dn) TLR2 (E) followed by treatment without () or
with () PE_PGRS33. Cell lysates were prepared, ASK1 was immunopre-
cipitated, and in vitro ASK1 kinase activity was determined using myelin
basic protein (MBP) as substrate as described under “Experimental Proce-
dures.” FandG, cellswere transfectedwithemptyvectoror kinase-deadASK1
(ASK1(KM)) as indicated, followed by treatment without or with PE_PGRS33
as statedunder E.Phospho-p38 (F) or phospho-JNK (G)was analyzedbyWest-
ern blotting as described under A and B. H, cells were transfectedwith empty
vectors or dominant-negative constructs indicated, followed by incubation
without () or with (f) PE_PGRS33 (1 g/ml) for 14 h. The release of TNF-
was measured in the supernatant. Blots shown are representative of the
results obtained in three separate sets of experiments. Lower blots of A, B, F,
andGwere probedwith nonphospho-antibodies to confirm equal loading in
all lanes. ForD and E, Western analysis with anti-ASK1 antibody (lower panels)
was performed to confirm equal loading in all lanes. For C and H, values are
means S.D. for three separate sets of experiments.
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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signals through TLR2, we asked the question whether PE_
PGRS33 was eliciting TLR2-dependent cell death independent
of TNF- release or whether the release of TNF- was neces-
sary for cell death. Pretreatment of RAW 264.7 with neutraliz-
ing antibody against TNF- abrogated PE_PGRS33-induced
cell death (Fig. 5B). This suggests that the release of TNF- is
essential for PE_PGRS33-dependent cell death. TNF- triggers
death receptor-dependent apoptosis by engaging TNFRI.
PE_PGRS33 was capable of up-regulating expression of the
TNFRI gene in a TLR2-dependent manner (Fig. 3). This was
associated with increased cell surface expression of TNFRI.
Surface expression of TNFRI was assessed by flow cytometry.
Cells after exposure to PE_PGRS33 were treated with rabbit
anti-TNFRI antibody followed by Alexa 488-conjugated sec-
ondary antibody. The binding of Alexa-488 served as ameasure
of surface exposure ofTNFRI. Therewas a 3-fold increase in the
surface expression of TNFRI in PE_PGRS33 -treated cells com-
pared with untreated cells. The percent of Alexa-488-positive
cells increased from 23  4 (untreated cells) to 73  4 (n  5,
p  0.001) in PE_PGRS33-treated cells. Control experiments
were performed using isotype IgG instead of TNFRI antibody,
and no increase in Alexa 488 staining was observed in the
absence or presence of PE_PGRS33.
PE_PGRS33-induced Cell Death Depends on ASK1/MAPK
Signaling and Activation of Caspases—Transfection of cells
withASK1(KM),p38(agf),andJNK(apf), inhibitedPE_PGRS33-
dependent cell death (Fig. 5C), suggesting a role of the ASK1/
MAPK signaling axis in the cell death process. At the same time,
pretreating cells with the caspase 3, 8, and 9 inhibitors
Z-DEVD-FMK, Z-IETD-FMK, and Z-LEHD-FMK, respec-
tively, led to an inhibition of PE_PGRS33-induced cell death as
assessed by measuring the binding of annexin-fluos (Table 3),
suggesting the likely involvement of all three caspases in the
death process.
PE_PGRS33-induced Cell Death in Macrophages Occurs in a
Mitochondria-dependentManner—The activation of caspase 9
in the intrinsic pathway of cell death is preceded by the mito-
chondrial permeability transition and loss of themitochondrial
FIGURE 5. PE_PGRS33-induced loss of mitochondrial membrane poten-
tial and cell death. RAW264.7 cells were either left untreated or treatedwith
PE_PGRS33 (1 g/ml) for different periods of time (A). In a separate experi-
ment, cells were either left untreated or pretreated with TNF- neutralizing
antibody (10g/ml) orwith isotype IgG (i/c) for 1 h (B) followedby incubation
with PE_PGRS33. In separate experiments, cells were also treated either with
PE_PGRS62 or PE_PGRS48. C, cells were transfected with empty vector or
dominant-negative constructs as indicated. Cells after transfection were
either left untreated () or treated with PE_PGRS33 (f). In each case, the
inducer was removed, and cells were washed and lysed, and cell death was
measured using the cell death ELISA kit from Roche Applied Science as
described under “Experimental Procedures.” Results are expressed as fold
increase in the release of histone in comparison with that of the control
(untreated RAW 264.7). *, p 0.001; **, p 0.01, versus control. D, cells were
treatedwith PE_PGRS33 for different periods of time. Cells werewashed, and
the fluorescence of DiOC6 was determined at excitation and emission wave-
lengths of 488 and 500 nm, respectively. Values for deenergized mitochon-
dria were determined by simultaneous treatment of cells with 10 M CCCP
and DiOC6. Values are given as means S.D. of three different experiments.
TABLE 3
PE_PGRS33- induced apoptosis in RAW 264.7 cells
Annexin V-fluos-positive
cells (%)a
Control 8 1
His-PE_PGRS33 70 8b
His-PE_PGRS33 anti-TNF-c 10 1d
His-PE_PGRS33 i/cc 72 6b
His-PE_PGRS33 z-IETD-FMK 15 3d
His-PE_PGRS33 z-LEHD-FMK 16 3d
His-PE_PGRS33 z-DEVD-FMK 13 2d
His-PE_PGRS33 PBe 70 6b
Heat-treated His-PE_PGRS33 7 1d
Irrelevant His-protein 8 1d
His-PE_PGRS (HEK) expressed in, and
purified from HEK 293
73 8b
a Results represent the means  S.D. of three separate determinations. His-
PE_PGRS33 and His-PE_PGRS (HEK) represent the proteins expressed in E. coli
and HEK293, respectively.
b Values are p 0.001 versus control.
c Cells were pretreated with anti-TNF- or isotype-matched antibody before treat-
ment with PE_PGRS33.
d Values are p 0.001 versus His-PE_PGRS33.
e PE_PGRS33 was incubated with polymyxin B resin before incubation with RAW
264.7.
TLR2-mediated TNF- Release byM. tuberculosis PE_PGRS33
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membrane potential (m) (38). Themitochondrial permeabil-
ity transition reduces the accumulation of the fluorescent dye
DiOC6 in themitochondria as a consequence of the loss ofm.
We observed the activation of caspase 9 as assayed byWestern
blotting to detect the cleaved form of caspase 9 (Fig. 6B). As a
positive control for monitoring loss of m, RAW 264.7 cells
were treated with CCCP, a proton ionophore that dissipates
m. A loss of DiOC6 fluorescence was observed (Fig. 5D). A
similar loss of m was evident from the time-dependent
reduction in accumulation of DiOC6 (Fig. 5D) in PE_PGRS-
challenged RAW 264.7 cells suggesting that the intrinsic path-
way is involved in PE_PGRS33-mediated cell death.
Caspase 8ActivationLinks theMitochondrial Pathway toDeath
Receptor Signals in PE_PGRS33-mediated Cell Death—The PE_
PGRS33-mediated activation of caspase 9 was inhibited by
caspase 8 inhibitor Z-IETD-FMK (Fig. 6B), suggesting that
death receptor-dependent apoptotic signals were likely ampli-
fied in a classical manner through caspase 8-triggered mito-
chondrial loss of m. Hallmarks of this pathway are the gen-
eration of truncated Bid (t-Bid), a proapoptotic member of the
Bcl-2 family and the release of cytochrome c (39, 40). We could
demonstrate the activation of caspase 8 (Fig. 6A), the genera-
tion of t-Bid (Fig. 6C), and the release of cytochrome c (Fig. 6C)
arguing in favor of PE_PGRS33 triggering a classical death
receptor-dependent signal undergoing amplification through the
mitochondrial pathway by caspase 8-dependent insertion of
t-Bid in the mitochondrial membrane.
Role of Caspase 3 in PE_PGRS33-mediatedCell Death—Con-
sistent with the effect of caspase inhibitors on PE_PGRS33-
induced cell death, Western analysis using antibodies specific
for the cleaved formof caspase 3 showed that PE_PGRS33 chal-
lenge activated the executioner caspase 3 (Fig. 6D). The gener-
ation of cleaved caspase 3 could be blocked by pretreatment
with the caspase 9-specific inhibitor Z-LEHD-FMK. Taken
together, these results suggest that sequential activation of
caspases 8, 9, and 3 downstreamof TNF--dependent signaling
is involved in PE_PGRS33-mediated cell death.
DISCUSSION
TNF- or TNFRs-deficient mice are compromised in their
ability to combat pathogens such as Listeria monocytogenes,M.
tuberculosis, M. avium, and Salmonella typhimurium. As
hypothesized by Rahman and McFadden in a recent review
(41), TNF signaling networks therefore provide a selection
pressure for pathogens to evolve strategies to combat the TNF-
mediated responses to infection. The PE_PGRS genes are
restricted to mycobacteria, raising the interest in their role in
the biology of M. tuberculosis. Clinical isolates undergo
sequence variation of the PE_PGRS genes (26, 42), and exten-
sive polymorphisms ofmembers of this family have been shown
in epidemiological studies (43). Comparison of the genome
sequences ofM. tuberculosisH37Rv andCDC1551 has revealed
that 39 of 62 PE_PGRS genes show extensive sequence diver-
gence that would result in the absence of a protein or a differ-
ence in size because of frame insertion or deletion or frameshift
(42). We have tested the hypothesis that polymorphisms in at
least one member of the PE_PGRS family, namely PE_PGRS33,
could give rise to differences in the immune response that they
elicit, focusing in this case on TNF-. We have concentrated
our efforts on PE_PGRS33, considering that it is surface-ex-
posed, expressed during infection (18), and shows variations in
its sequence among clinical strains (26).
The earliest phase of infection involves the interaction of the
surface-exposed moieties of M. tuberculosis with the PRRs of
macrophages. The outcome of these interactions dictates the
course of the infection. Considering that PE_PGRS33 is sur-
face-exposed, we felt that its effects on the early phases of the
infection could be simulated by challenging macrophages with
exogenous recombinant protein. The repertoire of immune
response modulators released by M. tuberculosis-challenged
FIGURE 6. PE_PGRS33-induced caspase activation and cleavage of Bid.
RAW 264.7 cells were either left untreated or treated with PE_PGRS33 (1
g/ml) for different periods of time. Cell lysates were prepared as
described under “Experimental Procedures.” In a separate set of experi-
ments, cells were pretreated with TNF- neutralizing antibody or with
isotype IgG (i/c) (A) as described under Fig. 4, with caspase 8 inhibitor
(Z-IETD-FMK, 50M) (B and C), or with caspase 9 inhibitor (Z-LEHD-FMK, 50
M) (D) for 1 h. Cleaved caspase 8 (20 kDa) (A) or caspase 9 (37 kDa, B), cyt
c (C), t-Bid (C), and caspase 3 (17 kDa) (D) were detected by Western blot-
ting using specific antibodies. Blots shown are representative of the
results obtained in three separate sets of experiments.
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macrophages is central to the innate immune response. Follow-
ing exposure of macrophages to recombinant PE_PGRS33, we
evaluated the release of a number of cytokines/chemokines.
PE_PGRS33 elicited the release of TNF- in a TLR2-dependent
manner. However, PE_PGRS33 did not induce the release of
macrophage inflammatory protein-1 and -1, monocyte che-
moattractant protein-1, interleukin (IL)-6, IL-8, and IL-12 from
RAW 264.7 (data not shown).
The role of TLR2 in PE_PGRS33-triggered TNF- release was
corroborated by challenging HEK293 cells expressing TLR2 with
PE_PGRS33. Considering that PE_PGRS33 expressed and puri-
fied fromHEK293 and fromE. coli exerted similar effects, the pos-
sibility of bacterial contaminants playing a role in the process
could be ruled out. Binding of PE_PGRS33 to TLR2-transfected
HEK293 cells could be demonstrated by flow cytometry (Table 2).
We extended our studies to evaluate whether point mutations,
deletions, and insertions (classified based on the gene sequence of
M. tuberculosis H37Rv as reference) in PE_PGRS33, reported in
clinical strains (26), impacted the TLR2-dependent signaling elic-
ited by PE_PGRS33. Although none of the point mutations had
anyeffect,deletionsranging from30to91aminoacids in thePGRS
domain attenuated TNF- release between 25 and 40%. The var-
iant protein carrying two insertions of Gly-Ala-Gly repeats at
two different positions did not show significant variation in
TNF--releasing ability compared with PE_PGRS33 from M.
tuberculosisH37Rv. It appears likely that the deletions analyzed
caused structural alterations sufficient to affect the TLR2-bind-
ing capacity of the variant proteins. However, detailed analysis
of the PE_PGRS33-TLR2 interaction interface will be required
before definitive conclusions can be drawn. The expression of
these variant proteins in clinical strains needs to be evaluated.
In some instances, these deletions are reportedly associated
with additional mutations (including insertions of Gly-Ala
repeats). Assuming that the variant PE_PGRS proteins are
expressed by clinical strains, our observations suggest that vari-
ations in the PGRS domain of PE_PGRS33 alter the levels of
TNF- induction and are therefore likely to have an impact on
the innate immune response and on the course of infection.
Our observation that M. smegmatis harboring PE_PGRS33
could elicit TNF- release from cytochalasin D-treated RAW
264.7 and that this could be inhibited by neutralizing antibody
against TLR2 supports the view that interaction of PE_PGRS33
with surface-exposed TLR2 triggers a signaling pathway that
constitutes at least one arm of signaling leading to TNF-
release, and that this pathway is of relevance in the context of
the intact bacterium challenging themacrophage. Also of inter-
est to the basic aspect of innate immunity was our observation
that TNF- release required the TLR 2/ASK1/p38-JNK signal-
ing axis, showing that ASK1 activation downstream of TLR 2
has a role in the innate immune response to M. tuberculosis
infection. This view is further supported by the recent report by
Yang et al. (44) showing that TLR2/ASK1 signaling contributes
to mycobacteria-induced IL-23 expression in macrophages.
TNF- is a cytokine that is now acknowledged to be central
to the outcome of tuberculosis. It plays a vital role by walling off
the granuloma and containing the infection. In the present
study, we explored whether it is part of an autocrine loop dic-
tating the fate of the macrophage. Apoptosis of macrophages
triggered by intracellular pathogens has been the subject of
intense investigation in recent times. The interplay between
pro-apoptotic and anti-apoptotic pathways in macrophages
challenged with pathogenic mycobacteria, although incom-
pletely understood to date, is nevertheless likely to have an
important bearing on the outcome of the infection. The role of
macrophage apoptosis in the context of M. tuberculosis infec-
tion is a complex one. Considering that the macrophage is its
intracellular niche, virulent mycobacteria would be envisaged
to thwart apoptosis in the early stages of infection. Indeed, vir-
ulent species of M. tuberculosis have been reported to evade
apoptosis. Apoptosis of macrophages also contributes to the
alternate pathway of T cell activation (14) giving reason to
believe thatM. tuberculosis would benefit from thwarting apo-
ptosis. With the increase in bacterial load, however, the need
for dissemination of the pathogen would lead to the pathogen
benefiting from apoptotic and/or necrotic death of macro-
phages. PE_PGRS33 triggered apoptosis inmacrophages. TLR2
may trigger apoptosis by direct recruitment of death effector
domain-containing adapter proteins such as Fas-associated
death domain (38). However, in the present instance, apoptosis
was dependent on TLR2-dependent TNF- release. The fact
that PE_PGRS33 also triggered increased TNFRI expression,
suggested that TNF-/TNFRI interactions were central to
PE_PGRS33-induced macrophage cell death.
Dheenadhayalan et al. (45) have reported thatM. smegmatis
expressing PE_PGRS33 elicits necrosis of murine bonemarrow
macrophages. Their studies and the results described in this
study likely reflect distinct roles of PE_PGRS33 at different
stages of infection. Dheenadhayalan et al. (45) addressed the
role of PE_PGRS33 in the context of internalized bacteria resid-
ing inmacrophages. The increased survival of the PE_PGRS33-
expressing bacteria prompted the authors to suggest that
necrosis of the host cell likely helps in persistence of the bacte-
rium. Enhanced TNF- release could only partially account for
the observed effects. On the other hand, our studies unequivo-
cally demonstrate that PE_PGRS33, a surface-exposed protein,
interacts with TLR2 to elicit distinct effects on murine RAW
264.7 cells and human monocyte-derived macrophages, which
are independent of internalization of the bacterium. The apo-
ptotic effects of exogenous PE_PGRS33 or M. smegmatis-ex-
pressing PE_PGRS33 are entirely dependent on TNF-.
Recombinant 19-kDa lipoprotein has also been reported to
induce macrophage apoptosis in a TLR2-dependent manner
(46), suggesting thatM. tuberculosis has a repertoire of modu-
lins that signal through TLRs to effect apoptosis.
Our observations are of potential clinical significance con-
sidering that deletions in the PGRS domain of PE_PGRS33 alter
the TNF--inducing properties of the protein. These studies
offer important insight into how sequence variations in the
polymorphic PGRS domain could modulate the immune
response and thereby the course of infection.
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